Literature DB >> 35857269

Pituitary surgery in Cushing's disease: first line treatment and role of reoperation.

Pamela S Jones1, Brooke Swearingen2.   

Abstract

Cushing's disease is the most common cause of endogenous hypercortisolemia, and transsphenoidal surgery remains the first line therapy for removal of the ACTH-secreting adenoma. While post-operative remission rates are high in experienced hands, there remains a 2% risk of recurrence per year. Patients with the highest chance for cure are those with small, non-invasive tumors that are visible on pre-operative MRI and identified during surgery and are performed by high-volume pituitary neurosurgeons. Surgery for persistent or recurrent disease is frequently indicated and is most successful in the hands of experienced surgeons and in cases where tumor is visible on MRI.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Cushing’s disease; Cushing’s recurrence; Cushing’s remission; Transsphenoidal

Year:  2022        PMID: 35857269     DOI: 10.1007/s11102-022-01254-8

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   3.599


  1 in total

1.  Treatment of recurrent and persistent Cushing's disease after first transsphenoidal surgery: lessons learned from an international meta-analysis.

Authors:  Carlos Perez-Vega; Andres Ramos-Fresnedo; Shashwat Tripathi; Ricardo A Domingo; Krishnan Ravindran; Joao P Almeida; Jennifer Peterson; Daniel M Trifiletti; Kaisorn L Chaichana; Alfredo Quinones-Hinojosa; Susan L Samson
Journal:  Pituitary       Date:  2022-05-04       Impact factor: 4.107

  1 in total
  1 in total

1.  Special issue: Cushing's disease update.

Authors:  Maria Fleseriu
Journal:  Pituitary       Date:  2022-08-24       Impact factor: 3.599

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.